Bristol-Myers Squibb

Here's Why Bristol Myers Offered MyoKardia $13.1 Billion
Motley Fool
Wed, 10/7/20 - 10:52 am
M&A
MyoKardia
Bristol-Myers Squibb
Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart
BioPharma Dive
Mon, 10/5/20 - 11:52 am
Bristol-Myers Squibb
M&A
MyoKardia
genetic heart disease
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Motley Fool
Sun, 10/4/20 - 10:59 pm
Bristol-Myers Squibb
FDA
Opdivo
Yervoy
mesothelioma
Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity
Xconomy
Sun, 10/4/20 - 12:11 am
Bristol-Myers Squibb
Celgene
clinical trials
clinical trial diversity
Samit Hirawat
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Fourth-quarter events to watch for big pharma
EP Vantage
Mon, 09/28/20 - 10:34 pm
COVID-19
clinical trials
AstraZeneca
Gilead Sciences
Takeda
GSK
Roche
Alzheimer's disease
Bristol-Myers Squibb
Pfizer
Eli Lilly
Bristol Myers Squibb's Opdivo cuts relapse risk in muscle-invasive bladder cancer
Fierce Pharma
Sat, 09/26/20 - 10:20 pm
Bristol-Myers Squibb
Opdivo
bladder cancer
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week
Fierce Pharma
Tue, 09/22/20 - 10:21 pm
drug pricing
regulatory
Celgene
Bristol-Myers Squibb
Teva Pharmaceutical
Amgen
Novartis
Mallinckrodt
AbbVie
US Congress
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Tue, 09/22/20 - 12:18 pm
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
Endpoints
Mon, 09/21/20 - 11:27 pm
Bristol-Myers Squibb
ESMO
Opdivo
esophageal cancer
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
Thu, 09/17/20 - 11:09 pm
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
FDA approves Onureg as continued treatment for adults in first remission with AML
Pharmaceutical Business Review
Wed, 09/2/20 - 10:37 am
Bristol-Myers Squibb
Onureg
FDA
AML
After Bristol snub, Gilead pens $120M upfront, $685M in biobucks for early Jounce cancer program
Fierce Biotech
Tue, 09/1/20 - 10:59 am
Jounce Therapeutics
Gilead Sciences
Bristol-Myers Squibb
biobucks
immuno-oncology
ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study
Fierce Pharma
Mon, 08/31/20 - 10:49 am
Pfizer
Bristol-Myers Squibb
Eliquis
Xarelto
site-specific bleeding
RWE
ESC
Go or no go? A quiet month ahead for US approval verdicts
EP Vantage
Fri, 08/28/20 - 10:29 am
FDA
Bristol-Myers Squibb
CC-486
AML
Mallinckrodt
terlipressin
Mesoblast
Ryoncil
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Bristol Myers Squibb's Idhifa Flunks Acute Myeloid Leukemia Trial
BioSpace
Tue, 08/25/20 - 11:14 am
Bristol-Myers Squibb
clinical trials
enasidenib
acute myeloid leukemia
Bristol Myers to buy Forbius in hunt for Opdivo-enhancing drugs
Fierce Biotech
Mon, 08/24/20 - 10:48 am
Bristol-Myers Squibb
M&A
Forbius
Opdivo
Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program
Fierce Biotech
Mon, 08/17/20 - 10:34 am
Bristol-Myers Squibb
Dragonfly Therapeutics
IL-12 immunotherapy
DF6002
FDA to decide on TG Therapeutics’ lymphoma drug early next year
Pharmaforum
Thu, 08/13/20 - 11:53 pm
TG Therapeutics
FDA
lymphoma
umbralisib
Bristol-Myers Squibb
Roche

Pages